Leap Therapeutics (LPTX) Price & Analysis

Compare

921 Followers

LPTX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.22 - $4.79

Previous CloseN/A

Volume72.74K

Average Volume (3M)5.24M

Market Cap

$31.08M

Enterprise Value-$5.54M

Total Cash (Recent Filing)$18.13M

Total Debt (Recent Filing)$39.00K

Price to Earnings (P/E)―

Beta1.88

Next Earnings

Nov 17, 2025

EPS Estimate

-0.24

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.40

Shares Outstanding41,439,530

10 Day Avg. Volume14,640,281

30 Day Avg. Volume5,242,276

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap-0.18

Enterprise Value/Revenue-554.10

Enterprise Value/Gross Profit-1.11K

Enterprise Value/Ebitda0.09

Forecast

1Y Price Target

$3.00

Price Target Upside334.78% Upside

Rating ConsensusHold

Number of Analyst Covering0

Bulls Say, Bears Say

Bulls Say

Drug DevelopmentPromising efficacy data point to market potential of DNK-01 in approximately 25%-50% of 2L patients.

Financial StabilityThe company reported approximately $47M in cash and cash equivalents at the end of 4Q24, which is believed to be sufficient to fund operations.

Bears Say

Pipeline DevelopmentUncertainties regarding the company's pipeline development and lack of meaningful catalysts contribute to the Neutral rating on LPTX.

Strategic PartnershipsThe company still needs to identify a partner to run the registrational Phase 3 study.

Leap Therapeutics News

Leap Therapeutics announces $58.88M private placement

Leap Therapeutics (LPTX) announced $58,888,888 in cash commitments for a private investment in public equity offering led by...

5d ago

LPTX

Leap Therapeutics Raises $58.88M in Private Placement

Leap Therapeutics ( ($LPTX) ) has shared an update. On October 6, 2025, Leap Therapeutics entered into a...

2d ago

LPTX

Leap Therapeutics Announces $58.88M Private Placement

Leap Therapeutics ( ($LPTX) ) has shared an announcement. On October 6, 2025, Leap Therapeutics announced a $58.88...

5d ago

LPTX

Leap Therapeutics Granted Extension by Nasdaq

The latest update is out from Leap Therapeutics ( ($LPTX) ). On March 12, 2025, Leap Therapeutics received...

29d ago

LPTX

Leap Therapeutics Reports Q2 2025 Financial Results

Leap Therapeutics ( ($LPTX) ) has released its Q2 earnings. Here is a breakdown of the information Leap...

2M ago

LPTX

Leap Therapeutics Completes Promising Phase 2 Cancer Study

Leap Therapeutics (($LPTX)) announced an update on their ongoing clinical study. Leap Therapeutics has recently completed a Phase...

2M ago

LPTX

Leap Therapeutics Winds Down R&D Amid Financial Strain

An update from Leap Therapeutics ( ($LPTX) ) is now available. Due to current market conditions and financial...

4M ago

LPTX

Leap Therapeutics to cut workforce by 75%, explore strategic alternatives

Leap is taking additional steps to reduce spending and preserve capital. Over the next two months as the...

4M ago

LPTX

Leap Therapeutics reports updated results from Phase B of DeFianCe study

Leap Therapeutics (LPTX) reported updated results from Part B of the DeFianCe study, a Phase 2 study of...

4M ago

LPTX

Leap Therapeutics Reports Increased Q1 Losses

Leap Therapeutics ( ($LPTX) ) has released its Q1 earnings. Here is a breakdown of the information Leap...

5M ago

LPTX

Leap Therapeutics Reports Positive Clinical Data and Financial Results

Leap Therapeutics ( ($LPTX) ) has released its Q4 earnings. Here is a breakdown of the information Leap...

7M ago

LPTX

Leap Therapeutics reports Q4 EPS (37c) vs. (46c) last year

“In 2024, we continued to advance sirexatamab, our anti-DKK1 antibody, through Phase 2 randomized controlled clinical trials as...

7M ago

LPTX

Leap Therapeutics updated preliminary data from Part B of the DeFianCe study

Leap Therapeutics (LPTX) presented updated preliminary data from Part B of the DeFianCe study, a Phase 2, open-label,...

7M ago

LPTX

LPTX Earnings this Week: How Will it Perform?

Leap Therapeutics (LPTX) is scheduled to report 4th quarter earnings on 03/24/2025. Regarding Q4 estimates, Wall Street analysts...

7M ago

LPTX

LPTX FAQ

What was Leap Therapeutics’s price range in the past 12 months?

Leap Therapeutics lowest stock price was $0.22 and its highest was $4.79 in the past 12 months.

What is Leap Therapeutics’s market cap?

Leap Therapeutics’s market cap is $31.08M.

When is Leap Therapeutics’s upcoming earnings report date?

Leap Therapeutics’s upcoming earnings report date is Nov 17, 2025 which is in 37 days.

How were Leap Therapeutics’s earnings last quarter?

Leap Therapeutics released its earnings results on Aug 14, 2025. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.29 by -$0.11.

Is Leap Therapeutics overvalued?

According to Wall Street analysts Leap Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Leap Therapeutics pay dividends?

Leap Therapeutics does not currently pay dividends.

What is Leap Therapeutics’s EPS estimate?

Leap Therapeutics’s EPS estimate is -0.24.

How many shares outstanding does Leap Therapeutics have?

Leap Therapeutics has 41,439,530 shares outstanding.

What happened to Leap Therapeutics’s price movement after its last earnings report?

Leap Therapeutics reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.29. Following the earnings report the stock price went down -29.412%.

Which hedge fund is a major shareholder of Leap Therapeutics?

Currently, no hedge funds are holding shares in LPTX

Leap Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-183.72%

Trailing 12-Months

Asset Growth

-75.39%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Leap Therapeutics

Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its lead clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric, hepatobiliary, gynecologic, and prostate cancers. Leap Therapeutics, Inc. has an option and license agreement with BeiGene, Ltd. to develop and commercialize DKN-01 in Asia (excluding Japan), Australia, and New Zealand. The company was formerly known as HealthCare Pharmaceuticals, Inc. and changed its name to Leap Therapeutics, Inc. in November 2015. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts.